SOM3355 200mg BID ( DrugBank: - )
1 disease
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 8 | Huntington disease | 1 |
8. Huntington disease
Clinical trials : 229 / Drugs : 193 - (DrugBank : 60) / Drug target genes : 84 - Drug target pathways : 158
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT03575676 (ClinicalTrials.gov) | August 8, 2018 | 11/6/2018 | Efficacy and Safety of SOM3355 in Huntington's Disease Chorea | Phase IIa, Double-blind, Randomized, Placebo-controlled Study of the Efficacy and Safety of SOM3355 in Huntington's Disease (HD) Patients With Chorea Movements. | Huntington's Chorea | Drug: SOM3355 100mg BID;Drug: SOM3355 200mg BID;Drug: Placebo BID | SOM Biotech SL | NULL | Completed | 18 Years | N/A | All | 32 | Phase 2 | Spain |